3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Genitourinary
1
Conditions
Vascular Calcification
1
Neoplasm Metastasis
1
Kidney Diseases
1
Hyperparathyroidism
1
Chronic Kidney Disease-Mineral and Bone Disorder
1
Bone Diseases
1
Interventions
Cyclophosphamide
517
Bevacizumab
488
Carboplatin
424
pembrolizumab
387
Paclitaxel
385
Gemcitabine
372
Cisplatin
366
Docetaxel
323
Rituximab
316
Radiotherapy
296
Nivolumab
247
Doxorubicin
243
Dexamethasone
240
Fluorouracil
225
Capecitabine
214
Oxaliplatin
211
Erlotinib Hydrochloride
206
fludarabine phosphate
201
Etoposide
188
Cetuximab
186
Lenalidomide
177
Pemetrexed
176
Bortezomib
174
Trastuzumab
173
Filgrastim
171
fludarabine
166
Prednisone
166
Leucovorin
166
Cytarabine
166
Irinotecan
161
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Has results
×
etelcalcetide hydrochloride
×
Clear all
NCT03960437
2023-09-21
Parsabiv-MBD
Columbia University
Phase 2
Completed
22 enrolled
14 charts